Related Experiment Video
Updated: Apr 23, 2026

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
Published on: July 30, 2016
Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms
Valeria C Sandrim1, Ana C T Palei, Nibia Eleuterio
1Departmento de Farmacologia, Instituto de Biociências, Universidade Estadual Paulista (UNESP), Botucatu, São Paulo, Brazil, valsandrim@yahoo.com.br.
Introduction:
Vascular endothelial growth factor (VEGF) is relevant for healthy pregnancy, and abnormalities in VEGF functions have been associated with hypertensive disorders of pregnancy. Our group recently demonstrated that VEGF genetic polymorphisms affect the susceptibility to preeclampsia (PE).
Objective:
Therefore, in this study our aim is to examine whether VEGF polymorphisms affect the antihypertensive responses in women with PE.
Methods:
We studied 113 white PE women who were stratified according to blood pressure levels after antihypertensive treatment (46 responsive, R group and 67 non-responsive, NR group). We then compared the frequencies of two VEGF genetic polymorphisms (C-2578A and G-634C) between R and NR groups.
Results:
We found no significant differences in genotype or allele distributions between R and NR groups (P > 0.05). In addition, no difference was observed in overall distribution of haplotypes (P > 0.05).
Conclusion:
Our data suggest that VEGF polymorphisms do not affect responsiveness to the antihypertensive therapy in PE.
More Related Videos
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hormonal Regulation
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Hypertension V: Nursing Management
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Direct Renin Inhibitors

